Susan Lerner

Susan Lerner is a hematology-oncology specialist focused on the genomic characterization of CLL and its clinical implications for treatment selection. Her research has contributed to understanding how IGHV mutation status, del17p/TP53 mutations, and complex karyotype predict outcomes and guide therapy choices in CLL. She has participated in clinical trials evaluating BTK inhibitors and venetoclax in genomically high-risk CLL populations. Her clinical program emphasizes personalized care using comprehensive genomic profiling at diagnosis.